Install
Send din pressemeddelelse med det samme Via Ritzau – den direkte linje til medierne.
- 270articles · 30d
- 5+ hour agolatest article
- Aug 18, 2026earliest in window
- 99%with images
- 248avg words
- Economy, Business & Finance 228
- Finance & Business 167
- News 115
- Business & Industrial 78
- Industrial 25
- Science & Technology 21
- Health & Wellness 20
- Medical 18
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
ONWARD Medical NV | Globenewswire
5+ day, 2+ hour ago (552+ words) ONWARD Medical Reports First Half 2026 Results with Strong Product Revenue Growth and Continued Progress across ARC Therapy Pipeline THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE 7(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014) EINDHOVEN, the Netherlands, Sept. 09, 2026 (GLOBE…...
Every Entrepreneur Needs Someone to Call: Lenovo and Eva Longoria Open a New Line of Support for Entrepreneurs with “Call Eva” | Business Wire
5+ day, 21+ hour ago (355+ words) 8.9.2026 12:00:00 CEST | Business Wire | Press release The latest Backing Every Business activation gives entrepreneurs a new way to seek advice, share challenges and bring their biggest business questions directly to fellow business owner, Eva Longoria. Running a business can feel lonely....
Pacera | Globenewswire
5+ day, 22+ hour ago (292+ words) Aico by Pacera Achieves SAP®-certified for Clean Core with RISE with SAP London - 08 September - Pacera announced today that its product Aico has been certified by SAP for clean core with RISE with SAP. The certification gives organisations running SAP…...
Greywolf Therapeutics | Globenewswire
6+ day, 1+ hour ago (417+ words) Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial OXFORD, United Kingdom, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Greywolf Therapeutics, the clinical-stage biotech company advancing novel antigen modulation treatments for cancer and autoimmune diseases, today reports significant progress in their Phase…...
Novo Nordisk A/S | Globenewswire
6+ day, 21+ hour ago (184+ words) The overall safety and tolerability of semaglutide observed in STEP Young were consistent with previous Novo Nordisk paediatric and adult trials with semaglutide and liraglutide, and no new safety concerns were identified. Furthermore, no safety concerns were identified for growth…...
Lipotype GmbH | Globenewswire
1+ week, 5+ day ago (237+ words) Research Team Wins Heinz Maurer Award for Linking Bacterium to Eczema Barrier Failure The team combined lipidomics, profiling the fatty molecules forming the skin's outermost layer, with microbiome profiling, identifying bacterial communities on the skin's surface. Both were performed on…...
Compass Pathways to Participate in 2026 Cantor Global Healthcare Conference on September 9, 2026 | Business Wire
1+ week, 5+ day ago (163+ words) 1.9.2026 12:30:00 CEST | Business Wire | Press release Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 2026 Cantor Global Healthcare Conference on September 9, 2026 and will…...
Medicel AG | Globenewswire
1+ week, 5+ day ago (436+ words) Medicel AG expands its SOFT TIP I/A portfolio with the launch of BICEL™ SOFT TIP I/A terralution™ – bimanual sustainable I/A (irrigation / aspiration) for gentle tissue interaction – at the ESCRS Congress 2026 in London. ALTENRHEIN, Switzerland, Sept. 01, 2026 (GLOBE NEWSWIRE)…...
INVENTIVA | Globenewswire
1+ week, 6+ day ago (96+ words) Inventiva Appoints Chris Benecchi as Chief Operating Officer With a potential U.S. launch of lanifibranor, subject to regulatory approval, anticipated in 2028, Inventiva is strategically building the organization, infrastructure, and commercial capabilities needed to support a successful launch and long-term market adoption....
BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer | Business Wire
1+ week, 6+ day ago (197+ words) 31.8.2026 12:00:00 CEST | Business Wire | Press release Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEAZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial Mark Lanasa, M.D., Ph....